Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33152244" target="_blank" >RIV/61989592:15110/14:33152244 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1002/ejhf.114" target="_blank" >http://dx.doi.org/10.1002/ejhf.114</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.114" target="_blank" >10.1002/ejhf.114</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.

Popis výsledku v původním jazyce

AIMS: Low systolic blood pressure (SBP) is associated with poor outcomes in heart failure and complicates management. In a post hoc analysis, we investigated the efficacy and safety of ivabradine in the SHIFT population divided by tertiles of baseline SBP. METHODS AND RESULTS: The analysis comprised 2110 patients with SBP {115 mmHg, 1968 with 115? SBP {130 mmHg, and 2427 with SBP ?130 mmHg. Patients with low SBP were younger, had lower ejection fraction, and were less likely to be at target beta-blockerdose than patients in the other SBP groups. Ivabradine was associated with a similar relative risk reduction of the composite outcome in the three SBP groups [SBP {115 mmHg, hazard ratio (HR) = 0.84, 95% confidence interval (CI) 0.72-0.98; 115? SBP {130mmHg, HR = 0.86, 95% CI 0.72 to 1.03; SBP ?130 mmHg, HR = 0.77, 95% CI 0.66 to 0.92; P interaction = 0.68]. Similar results were found for cardiovascular mortality (P interaction = 0.91), hospitalization because of heart failure (P inter

Název v anglickém jazyce

Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.

Popis výsledku anglicky

AIMS: Low systolic blood pressure (SBP) is associated with poor outcomes in heart failure and complicates management. In a post hoc analysis, we investigated the efficacy and safety of ivabradine in the SHIFT population divided by tertiles of baseline SBP. METHODS AND RESULTS: The analysis comprised 2110 patients with SBP {115 mmHg, 1968 with 115? SBP {130 mmHg, and 2427 with SBP ?130 mmHg. Patients with low SBP were younger, had lower ejection fraction, and were less likely to be at target beta-blockerdose than patients in the other SBP groups. Ivabradine was associated with a similar relative risk reduction of the composite outcome in the three SBP groups [SBP {115 mmHg, hazard ratio (HR) = 0.84, 95% confidence interval (CI) 0.72-0.98; 115? SBP {130mmHg, HR = 0.86, 95% CI 0.72 to 1.03; SBP ?130 mmHg, HR = 0.77, 95% CI 0.66 to 0.92; P interaction = 0.68]. Similar results were found for cardiovascular mortality (P interaction = 0.91), hospitalization because of heart failure (P inter

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Heart Failure

ISSN

1879-0844

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

810-816

Kód UT WoS článku

000339094200015

EID výsledku v databázi Scopus

—